What Happened?
Cambridge, CA-based Beigene Retired Howard Liang as Chief Financial Officer and Chief Strategy Officer
Date of management change: March 30, 2021
Cambridge, CA-based Beigene Retired Howard Liang as Chief Financial Officer and Chief Strategy Officer
Beigene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Our 5,400+ employees around the world are committed to expediting the development of a diverse pipeline of novel therapeutics. We currently market two internally discovered oncology medicines: BTK inhibitor BRUKINSA® (zanubrutinib) in the United States and China, and anti-PD-1 antibody tislelizumab in China. We also market or plan to market in China additional oncology products in China licensed from Amgen Inc., Celgene Logistics Sàrl, a Bristol Myers Squibb (BMS) company, and EUSA Pharma; and have entered a collaboration with Novartis Pharma AG for Novartis to develop and commercialize tislelizumab in North America, Europe, and Japan.
Howard Liang is President and Chief Financial Officer at Tessera Therapeutics. Previously, Howard held various senior HR leadership roles in the industry.
News
Other IT executives who recently changed jobs as well: Frank Michael, Hudgens Mary, Dimacale Chris, Lucht Daniel, Zenz Becky, Heimerman Steve, Sadiq Sabah, Joachim Stanley, Beliveau Joe, Olyha John, Desbiens Pierre-Yves
You can find the full directory of IT executives here.
How would you like to connect with 15,000+ IT executives in charge of $ millions in IT budgets? Find details here.